|

ADJUVANT ENDOCRINE THERAPY Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Anastrozole, Exemestane, Letrozole, Leuprolide, or other LHRH agonist (per investigator discretion), Tamoxifen

Pipeline

Phase 2: 1

Top Sponsors

  • Dana-Farber Cancer Institute1

Indications

  • Hormone Receptor Positive Breast Cancer1
  • Micrometastasis Breast Cancer1
  • Node Negative Breast Cancer1
  • Invasive Carcinoma of the Breast1
  • HER2-positive Breast Cancer1

Stamford, Connecticut1 trial

A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer

Stamford Hospital

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.